Scholarlink

Background <p>Systemic corticosteroids are cornerstone therapies in pediatric inflammatory diseases. Despite their clinical importance, both parents and clinicians may harbor substantial concerns regarding steroid-related adverse effects. While “steroidophobia” has been extensively studied in the context of topical corticosteroids, no validated instrument exists to assess clinician-based attitudes toward systemic corticosteroid use. This study aimed to develop and validate novel psychometric tools to measure systemic steroidophobia among clinicians.</p> Methods <p>A methodological, multicenter study was conducted between June and October 2025 among pediatric rheumatology specialists and fellows. Two draft instruments were developed: the Oral Corticosteroid Phobia Scale (21 items) and the Intravenous Corticosteroid Phobia Scale (22 items). Face and content validity were evaluated through expert review. Item analysis, exploratory and confirmatory factor analyses, internal consistency (Cronbach’s alpha), and test–retest reliability were performed.</p> Results <p>A total of 121 clinicians participated. After item reduction, the oral scale comprised 15 items and the intravenous scale 16 items, each demonstrating a two-factor structure. The Oral Corticosteroid Phobia Scale explained 63.5% of total variance (Cronbach’s alpha = 0.908), and the Intravenous Corticosteroid Phobia Scale explained 66.4% (Cronbach’s alpha = 0.935). Test–retest reliability was excellent (ICC = 0.902 and 0.930, respectively). Model fit indices indicated good construct validity. Lower phobia scores were observed among clinicians with longer pediatric rheumatology experience.</p> Conclusions <p>The developed scales demonstrated acceptable validity and reliability for assessing clinician-based systemic steroidophobia. These tools may facilitate a more systematic and objective identification of attitudinal barriers toward corticosteroid use and may serve as formative educational instruments in residency training and continuing medical education. Further validation across different pediatric subspecialties and countries is warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systemic steroidophobia scale for pediatric rheumatology (SSS-PR): development and validation of a novel psychometric tool measuring clinician steroidophobia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月26日

查看全文
  • Sema Nur Taşkın,
  • Sevil Aydoğan Gedik,
  • Emrah Atay,
  • Zeynep Kasap Acungil,
  • Nuray Aktay Ayaz

摘要

Background

Systemic corticosteroids are cornerstone therapies in pediatric inflammatory diseases. Despite their clinical importance, both parents and clinicians may harbor substantial concerns regarding steroid-related adverse effects. While “steroidophobia” has been extensively studied in the context of topical corticosteroids, no validated instrument exists to assess clinician-based attitudes toward systemic corticosteroid use. This study aimed to develop and validate novel psychometric tools to measure systemic steroidophobia among clinicians.

Methods

A methodological, multicenter study was conducted between June and October 2025 among pediatric rheumatology specialists and fellows. Two draft instruments were developed: the Oral Corticosteroid Phobia Scale (21 items) and the Intravenous Corticosteroid Phobia Scale (22 items). Face and content validity were evaluated through expert review. Item analysis, exploratory and confirmatory factor analyses, internal consistency (Cronbach’s alpha), and test–retest reliability were performed.

Results

A total of 121 clinicians participated. After item reduction, the oral scale comprised 15 items and the intravenous scale 16 items, each demonstrating a two-factor structure. The Oral Corticosteroid Phobia Scale explained 63.5% of total variance (Cronbach’s alpha = 0.908), and the Intravenous Corticosteroid Phobia Scale explained 66.4% (Cronbach’s alpha = 0.935). Test–retest reliability was excellent (ICC = 0.902 and 0.930, respectively). Model fit indices indicated good construct validity. Lower phobia scores were observed among clinicians with longer pediatric rheumatology experience.

Conclusions

The developed scales demonstrated acceptable validity and reliability for assessing clinician-based systemic steroidophobia. These tools may facilitate a more systematic and objective identification of attitudinal barriers toward corticosteroid use and may serve as formative educational instruments in residency training and continuing medical education. Further validation across different pediatric subspecialties and countries is warranted.